Abstract. In this study, we investigated whether tacrolimus extracted and purified from the commercial capsules (Prograf® 5 mg) have retained its original quality and activity beyond the capsules expiration date in order to be reused for research purposes after extraction. High-performance liquid chromatography (HPLC) assay method was developed and validated for the quantification of tacrolimus, using cyclosporine A as an internal standard (IS). Moreover, a combination of analytical methods, including nuclear magnetic resonance (NMR), gas chromatography-mass spectrometry (GC-MS), Fourier transform-infrared (FT-IR) spectroscopy, X-ray diffraction (XRD), and differential scanning calorimetry (DSC) were used to assess the quality of extracted/purified tacrolimus. Suppression of murine peripheralblood mononuclear cells (PBMC) proliferation and the levels of interleukin-2 (IL-2) and interferon gamma (IFN-γ) were also assessed. The data obtained showed no detectable differences in the quality profile between the authentic sample and extracted drug. Also, the results showed that the extracted/ purified tacrolimus was able to suppress T cell proliferation, induced by concanavalin A, indicating the retained pharmacological activity. We proved that tacrolimus extracted/purified from expired Prograf® capsuled retains its purity and immunosuppressive activity and can be reused for research and possibly in pharmaceutical manufacturing.
INTRODUCTION
Tacrolimus (Fig. 1a) is a potent immunosuppressive agent used clinically to reduce the risk of organ rejection in postoperative transplants patients (1) . It is also used to treat different skin disorders such as atopic dermatitis (2) , psoriasis (3) , and vitiligo (4) . Although both tacrolimus and cyclosporine A (CyA; Fig. 1b ) inhibit T cell activation through calcineurin inhibition, each drug binds to a different target molecule. While CyA binds to cyclophilin, tacrolimus binds to FK506-binding protein (5) . Clinical studies have shown that tacrolimus holds better safety and efficacy profiles compared to CyA (6) . Consequently, tacrolimus is a relatively expensive molecule since the average cost of 5 mg of tacrolimus monohydrate is EUR 256.00 (USD 288.60) (7) .
Tons of expensive medications are being disposed annually because they passed their expiration date although the printed expiration date may not necessarily represent the ultimate shelf life (8, 9) . The main purpose of this study is to investigate whether tacrolimus, extracted from expired commercial Prograf® capsules (5 mg), retains purity and pharmacological activity. For this purpose, a highperformance liquid chromatography (HPLC) assay method was developed and validated for the quantification of tacrolimus, using cyclosporine A as an internal standard (IS). Moreover, a combination of analytical methods, including, nuclear magnetic resonance (NMR), gas chromatographymass spectrometry (GC-MS), X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), and differential scanning calorimetry (DSC) were used to assess the quality of tacrolimus. Lymphocyte proliferation assay of mouse peripheral-blood mononuclear cells (PBMCs) and enzyme-linked immunosorbent assay (ELISA) to determine the levels of interleukin-2 (IL-2) and interferon gamma (IFN-γ) was also performed to further assess the pharmacological activity of the extracted drug. These tests assessed the purity and activity of tacrolimus extracted from Prograf® capsules beyond their expiration date.
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MATERIALS AND METHODS

Materials
Tacrolimus reference standard (FK-506 monohydrate ≥98% (HPLC)), cyclosporine A, carboxyfluorescein diacetate succinimidyl ester (CFSE) and concanavalin A (ConA) were purchased from Sigma (TX, USA). Acetonitrile (HPLC grade) was supplied by Fisher Scientific Co. (Leicestershire LE/15 RG, UK). 2-Propanol (HPLC grade) was supplied by PANREAC Quimica SA Co. (Barcelona, Spain). Anti-mouse CD4-APC and CD8-PE-CY7 were purchased from R&D systems (MN, USA). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin, and streptomycin were purchased from Gibco®, Life Technologies (CA, USA). IFN-γ and IL-2 Platinum ELISA kits were purchased from Affymetrix® eBioscience (CA, USA). Deionized water was prepared in-house using Millipore system. Prograf® capsules (batch # 7241, expiry date 06/2010; batch # 4104, expiry date 08/2012; and batch # 6875, expiry date 04/2015) were kindly provided by King Khalid University Hospital Pharmacy, King Saud University, Riyadh, Saudi Arabia. Non-expired Prograf® capsules (batch # 9311, expiry date 08/2017) were purchased from Hikma Pharmaceuticals, Riyadh, Saudi Arabia. BALB/c mice were kindly provided by the College of Pharmacy Animal House, King Saud University, Riyadh, Saudi Arabia.
Methods
Tacrolimus Capsule Content Measurement
To determine the amount of tacrolimus in capsules or extract, a previously reported colorimetric assay based on sulfuric acid reaction was used (10) with minor modification. Briefly, the contents of 5 mg tacrolimus expired capsules or extract were dissolved in 1 mL ethanol. The mixture was then vigorously vortexed and subjected to centrifugation at 20,000×g for 15 min at 4°C. The supernatants were diluted 20-fold in acetonitrile. Aliquots of tacrolimus solution (0-100 μL) were transferred to 4-mL glass vials, 40 μL of sulfuric acid was added, and the mixture was diluted to 1 mL with acetonitrile. Samples (400 μL) were transferred to UV cuvette and measured at 295 nm against a solvent blank. The percent mean active ingredient in expired Prograf® capsules or extract was compared with non-expired Prograf® capsules.
Extraction of Tacrolimus from Prograf® Capsules
The powder of Prograf® capsules was extracted with ethyl acetate (150 mL×4) by using a shaking water bath (GFL, Burgwedel, Germany) at a temperature of 40°C for 30 min. The extraction with ethyl acetate was repeated four times. The combined ethyl acetate extracts were dried by sodium sulfate, filtered and evaporated to dryness by using a rotary evaporator (Buchi, Flawil, Switzerland) at 40°C.
Purification and Isolation of Tacrolimus
The ethyl acetate extract was subjected to column chromatography (2.0×60 cm) on a pre-packed silica gel column (80 g silica gel 60 F254, Merck, Germany). The elution was performed with a gradient of chloroform-methanol (90:10) to pure methanol (v/v). Fractions were pooled into major fractions based on their thin-layer chromatography profiles (TLC, silica gel 60 F254, Merck, Germany) compared with tacrolimus standard. TLC analysis of the fractions with vanillin/ sulfuric acid (2%) and heating at 100°C, allowed the constitution of four fractions. The tacrolimus subfraction was further purified by using chromatotron (Harrison Research, USA) (silica gel 60 F254, layer thickness 2 mm, Merck, Germany). The elution was performed with a mobile phase composed of chloroform-methanol (98:2, v/v). The TLC analysis with an elution system of chloroform-methanol (90:10) showed a pure violet spot with R f value of 0.61 which was attributed to tacrolimus. 
NMR Spectroscopy
1 H NMR analysis was performed with a Bruker Ultra shield 500.133 MHz spectrometer in pyridine-d5 with TMS as internal standard. Baseline correction, calibration, and processing were performed using Topspin software.
GC-MS/MS
Analyses were conducted directly at a mass spectrometer (Varian 320 TQMS). The sample corresponding to a powder particle of tacrolimus was put in direct probe and introduced into the mass spectrometer directly starting from temperature 10 to 450°C at the rate of 10°C/min. Electron ionization of the mass spectrometer operated at the ionization energy of 70 eV, temperature of the ion source of 200°C, and the transfer line temperature is at 150°C. The mass range in direct probe is set at the range of mass of m/z 25-900.
X-ray Diffractometery
X-ray diffractometer was used to study the crystallinity state of the extracted tacrolimus. Tacroliums powder sample was loaded in the XRD instrument (automated Rigaku Ultima IV). The X-ray diffractogram of the investigated sample was collected using 2θ scan axis mode, scan speed set at 0.5°/ min, and covering scan range of 3.0-60.0°. The scanning process was performed at room temperature.
FT-IR Spectroscopy
The FT-IR spectrum of the extracted tacrolimus was obtained using an FT-IR spectrophotometer (PerkinElmer, USA). Tacrolimus sample was ground with potassium bromide (spectroscopic grade) and compressed into a thin disk using hydraulic press before scanning from 4000 to 600 cm −1 .
Differential Scanning Calorimetry
Thermogram of the extracted tacrolimus was obtained using differential scanning calorimetry (DSC-60, Shimadzu, Japan). Tacrolimus sample (3-5 mg) was loaded in an aluminum pan and sealed with aluminum lids by a crimper. The sample then thermally scanned against an empty aluminum pan with lid, at a heating rate of 10°C/min, covering temperature range of 25-200°C . Nitrogen purging at 40 mL/min was used during scanning. The TA-60WS thermal analysis software was used to calculate the thermal parameters of the scanned sample.
Chromatographic Apparatus and Conditions
Tacrolimus was determined using a reverse-HPLC method. The HPLC system (Waters™ 1500 series controller, USA) equipped with wavelength detector (Waters™ 2489 a Dual™ Absorbance detector, USA), pump (Waters™ 1525 a Binary pump, USA), an automated sampling system (Waters™ 2707 Plus Autosampler, USA). The HPLC system was monitored by BBreeze (Waters™)^software. Tacrolimus was analyzed by injecting 100 μL of drug solution using a mobile phase consisted of acetonitrile:deionized water:isopropyl alcohol (60:30:10v/v) adjusted to pH of 3 by phosphoric acid and pumped through a reversed-phase C 18 column (MachereyNagel, 4.6×150 mm, 10-μm particle size) at a flow rate of 1.0 mL/min. Tacrolimus concentration was detected using UV detector adjusted at 215 nm. The column temperature was adjusted at 60°C.
Standard and Stock Solutions
Stock solutions of tacrolimus (1 mg/mL) and cyclosporin A (1 mg/mL) as an internal standard (IS) were prepared in acetonitrile. These stock solutions were stored at −20°C in the dark. Each day, working solutions of tacrolimus (20 μg/mL) and IS (100 μg/mL) were freshly prepared before analysis. Set of calibrating standards at 100, 200, 500, 2500, 1000, 5000, and 10,000 ng/mL of tacrolimus, each containing 5 μg/mL of IS. Three concentrations of tacrolimus (100, 1000, and 10,000 ng/ mL) were chosen from calibration curve points as quality control samples (QCs).
Validation of the Assay Method
The method was validated according to the US Food and Drug Administration (FDA) guidelines for bioanalytical method validation (11) . Linearity of the assay method was determined by repeated assay of six standard curves on six separate days. The three points of QC samples were analyzed thrice with each standard curve. A linear regression was obtained by plotting the peak area ratio of the drug to IS versus drug concentration. The best weighting factor for linear regression was determined according to the results and to the variation of variance with respect to concentration, which was found to be 1/concentration. Intra-and inter-day precision (coefficient of variation (CV%)) and accuracy (expressed as bias%) were evaluated using three points of QC samples. Six replicates of each point were assayed in one run for the intraday experiment. Three replicates of each point of QC samples were assayed every day for six different days (inter-day experiment). According to FDA guidelines, the accuracy and imprecision for all tested concentrations should be within ±15% with the exception of the lower limit of quantification (LLOQ) sample, in which these parameters should not exceed 20%.
T Cell Proliferation
Peripheral blood mononuclear cells (PBMCs) were isolated from pooled whole blood samples of five mice (1.5 mL/ mice) using Ficoll density gradient centrifugation. PBMCs were incubated with pre-warmed PBS containing carboxyfluorescein diacetate succinimidyl ester (CFSE) dye (2 μM) for 8 min at 37°C. Cells were washed with PBS and treated with extracted tacrolimus at a concentration of 25 ng/mL for 2 h as described in (12) . Thereafter, cells were washed with PBS and subsequently stimulated with ConA super antigen (10 μg/mL/ 10 6 cells). The cells were then incubated for 4 days at 37°C. Standard surface staining protocol was followed for CD4 + and CD8 + T cells using anti-mouse CD4-APC and CD8-PE-CY7 monoclonal antibodies. Frequency of proliferative lymphocytes was determined using flow cytometry (LSRII BD biosciences) by acquiring up to 10 6 events for each condition.
Data were then analyzed using DIVA software (BD Biosciences). The animal studies were performed based on protocols approved by The Experimental Animal Care Center Review Board, College of Pharmacy, King Saud University (no. C.P.R.-3526).
ELISA
Mice PBMCs were isolated and suspended in complete DMEM media containing 10% gamma-irradiated FBS, 10 units/mL penicillin, and 10 μg/mL streptomycin at 37°C. Cells were treated as described earlier and then incubated at 37°C for 48 h. Supernatants were collected at 0, 24, and 48 h and IFN-γ and IL-2 levels were determined according to the manufacturer instructions.
Statistical Data Analysis
Data were analyzed for statistical significance (p<0.05) by Student's t test (SPSS for Windows, Version 16.0). Where indicated, the results were summarized as mean±SD. Table I lists the average percent active ingredient (tacrolimus) in extracted drug from expired capsules (batch #7241; expiry 06/2010) compared with Prograf®. The experiment was performed in August 2014. The calculated extraction recovery of drug from expired and non-expired capsules were 85.9 and 90.4%, respectively. Table II lists the percent mean tacrolimus content in different batches of expired Prograf® capsules. The experiment was performed in September 2015. Prograf® batches #7241 and #4104 were indeed expired since the percent mean content of tacrolimus was less than 90%. Interestingly, however, the percent mean content of tacrolimus in batch # 6875 was found to be higher than 93% (range 91-99%). Although it is more than 4 months past the printed expiry date, it still has over 93% of the label claim. Tacrolimus was successfully extracted/purified from expired Prograf® capsules as confirmed by TLC analysis ( Figure S1 ). The method used for extraction/purification was associated with high purity and yield as confirmed by HPLC and spectrophotometric analyses (discussed below). Figure 2 shows an overlay of NMR spectrum of authentic and extracted tacrolimus. By examination of the spectra, they clearly show identical signals, which are also comparable to the previously published NMR data (13) . (14) . The X-ray diffractogram of the extracted tacrolimus (Fig. 3 ) reveals clear diffraction peaks at 5-30 2θ°. This profile reflects a high degree of crystallinity (15) . Figure S2 shows the FT-IR spectrum of the extracted drug. All the major absorption bands associated with tacrolimus molecule are present, namely, 3461.50 cm (C=O), and 1640.38 cm −1 (C=C). Moreover, the spectrum also shows an identical fingerprint of tacrolimus compared to reference IR spectrum. DSC profile of the extracted tacrolimus (Fig. 4) shows a broad endothermic peak stretched from 49 to 100°C, which could be attributed to the solvent evaporation, followed by a significant endothermic peak at 126°C, which is the melting point reported for tacrolimus in DrugBank database (http:// www.drugbank.ca/drugs/DB00864).
RESULTS
Extraction and Purification of Tacrolimus from Prograf® Capsules
Characterization of Extracted/Purified Tacrolimus
Beside the molecular ion of tacrolimus (m/z 804.3), five main degradation products were obtained. The identified fragments were: m/z 142−1 (O- H), 3080 cm −1 (CH=),
HPLC Analysis Validation
At the beginning, a number of mobile phases composed of acetonitrile, methanol, and water at different ratios were tested. Best results were obtained when an isocratic acetonitrile:water:isopropyl alcohol (60:30:10) mobile phase was used. The addition of isopropyl alcohol and adjustment of the pH at 3 resulted in sharper peaks and shorter retention times for tacrolimus as well as cyclosporine A (IS). Tacrolimus and the IS were well separated with retention times of around 5.3 and 10.5 min, respectively. The linearity of the calibration curve was eva luat ed by s even-point standar ds; covering a The experiment was performed in August 2014. The percent mean active ingredient in expired Prograf® capsules or extract was compared with non-expired Prograf® capsules determined by a colorimetric assay N number, SD standard deviation, CV% coefficient of variation concentration range of (0.1-10 μg/mL) of tacrolimus, each calibration curve was evaluated six times. The linear regression of the calibration curves produced a mean slope and intercept of 0.00008 and 0.0032, respectively, with correlation coefficient (R 2 ) of 0.9996. The assay CV% for both intra-day and inter-day assessments was less than 12% including the lowest concentration used in the calibration and validation samples (0.1 μg/mL). Mean error was less than 5% in all the concentrations over 0.1 μg/mL (Table III) . The low variability in the validation data demonstrated the accuracy and reproducibility of the developed method. The method's lower limit of quantitation (LLOQ), i.e., the minimum level at which tacrolimus could be detected with acceptable accuracy and precision, was set at 0.1 μg/mL. The purity of extracted tacrolimus was assessed by comparing the average peak area obtained from 5 μg/mL sample of the extract with that of standard tacrolimus. The purity of the extract was estimated to be ∼83.6%.
Pharmacological Assessment of Extracted/Purified Tacrolimus
To test the bioactivity of extracted tacrolimus, T cell proliferation assay was performed. As shown in Fig. 5 , the ConA-induced proliferation of CD4 + T cells (Fig. 5a ) and CD8 + T cells (Fig. 5b ) was dramatically suppressed in response to pre-incubation with the extracted/purified tacrolimus. The suppressive effect was demonstrated by ∼2.5-fold and 1.5-fold decrease in the proliferation of CD4 + T cells and CD8 + T cells, respectively. Similarly, suppression of IL-2 secretion in T cell culture supernatants was determined as another indicator of proliferation (Fig. 6) . Although IL-2 levels were increasing in a timely The experiment was performed in September 2015. The percent mean active ingredient in different batches of expired Prograf® capsules was compared with non-expired Prograf® capsules determined by a colorimetric assay N number, SD standard deviation, CV% coefficient of variation Fig. 2 . The 0-11 ppm region of the 500 MHz 1 H NMR spectrum of a extracted tacrolimus, b reference standard, and c an overlay of (a) and (b). Protonated pyridine signals are marked with asterisks. The spectra of the reference standard and the extracted tacrolimus are identical fashion upon ConA stimulation in both tacrolimus-treated and untreated groups, pre-incubation with the extracted/ purified tacrolimus has successfully suppressed T cell proliferation by ∼4.2 folds. As IL-2 is upregulated in proliferating T cells (discussed below), the reduced levels of IL-2 tacrolimus-treated group is consistent with its suppressive effect on T cell proliferation shown in (Fig. 5) . Furthermore, IFN-γ levels were also determined. Figure 7 shows a significant suppression of IFN-γ secretion the group pre-incubated with the extracted/purified tacrolimus where IFN-γ levels were ∼22 folds less than the untreated counterparts.
DISCUSSION
The main purpose of this study was to investigate the possibility of reusing tacrolimus, the active ingredient, from expired Prograf® capsules. Multiple physical, chemical, and biological analyses were employed to assess the quality, purity, and pharmacological activity of the active pharmaceutical ingredient (API) following extraction and purification. The suitable selection of the chromatographic fractions eluted from silica gel column was determined by means of a TLC analysis. The purity was further confirmed by validated HPLC assay against tacrolimus standard. The chromatograms of the extracted drug and the reference standard both showed a single peak with a retention time of ∼5 min. The purity of the extract was estimated to be 83.6%. This is very close to the value estimated from the colorimetric assay, which was 85.9%. The recovery of tacrolimus following extraction from nonexpired and expired capsules was 90.4 and 85.9%, respectively, which indicates a high purity and yield of extract (Table I ). The percent mean tacrolimus content in two batches of the expired capsules used in this study was found to be less than 90%, which confirms that the capsules are expired (Table II) . The percent mean content of tacrolimus in the third batch used in current study was found to be higher than 93% (range 91-99%). Bearing in mind that the shelf life of the marketed drug (Prograf®) is only 3 years, and knowing that the analysis of capsule content was performed in September 2015, i.e., more than 4 months past the printed expiry date, this indicates that 3 years is probably a conservative period.
Several NMR studies for structure determination and synthesis of tacrolimus were performed by several groups, e.g., Nakatsuka et al. (16) and Mierke et al. (17) in the early 1990s. In these studies, tacrolimus was dissolved in deuterated chloroform and methanol due to the limited aqueous solubility of tacrolimus. In 2012, Ferraboschi et al. (13) have shown that using deuterated pyridine as a solvent for tacrolimus enhanced the resolution of proton resonances for tacrolimus API and related impurities compared to methanol or chloroform. Therefore, deuterated pyridine was used in the current study for the NMR analysis of tacrolimus. As shown in Fig. 2 , there was no detectable difference between the reference sample and the extracted drug.
Recently, B er et al. (14) performed a characterization study for tacrolimus raw material using thermal analysis and pyrolysis coupled to GC-MS. They studied the thermal decomposition of tacrolimus at two different temperatures 300 and 400°C. Under the conditions reported by B er et al., the molecular ion of tacrolimus (m/z 804) was not detected. Nonetheless, five main degradation products were obtained. (14) . In our study, the five main degradation fragments reported in B er et al. study were obtained. Interestingly, under the conditions used in the current study, the molecular ion of tacrolimus (m/z 804.3) was also Fig. 3 . XRD spectrum of extracted tacrolimus showing numerous sharp peaks at different diffraction angle indicating its crystalline nature. The diffractogram was collected using 2θ scan axis mode, scan speed set at 0.5°/min, and covering scan range of 3.0-60.0°. The scanning process was performed at room temperature Fig. 4 . DSC profile of extracted tacrolimus showing the characteristic endothermic peak at 126°C, with corresponds to the melting point of tacrolimus. The sample were thermally scanned against an empty aluminum pan with lid, at heating rate of 10°C/min, covering temperature range of 25-200°C detected. This is likely because milder conditions were used in the current study.
Extracted/purified tacrolimus exhibited distinct characteristic peaks in XRD diffractogram and endothermic peak in DSC thermogram, suggesting the crystal nature of the drug. The melting point observed in our work was found to be 126°C, which is identical to the melting point reported by Drug Bank database (http://www.drugbank.ca/ drugs/DB00864). Other investigators reported 126.6°C (13), 129°C (18), and 129.6°C (19) as melting point of tacrolimus. Overall, it could be concluded form DSC and XRD results that the powder of the extracted/purified tacrolimus is present in a crystalline state.
Tacrolimus is a known immunosuppressive agent commonly prescribed to organ transplant patients including the liver, kidney, heart, small bowel, pancreas, lung, skin, Intra-and inter-day precision (coefficient of variation (CV%)) and accuracy (expressed as bias%) were evaluated using three points of QC samples. Six replicates of each point were assayed in one run for the intra-day experiment. Three replicates of each point of QC samples were assayed every day for six different days (inter-day experiment) bone marrow, and limb transplants (20) . The immunosuppressive action of tacroliums is mediated by calcineurin inhibition, which leads to the suppression of T cell proliferation and T cell activation (21) (22) (23) . In our study, we explored whether tacrolimus retains the immunosuppressive effect after extraction and purification from expired Prograf® capsules. Therefore, PBMCs were isolated from mice blood and incubated with extracted/purified tacrolimus as mentioned earlier. Subsequently, the suppressive effect of tacrolimus on cell proliferation was challenged with ConA. ConA is a lectin carbohydrate-binding protein that was originally extracted from the jack bean. It has been widely used as a mitogen to stimulate T cells. It acts by cross-linking T cell receptor leading to antigenindependent T cell proliferation (24) . Tacrolimus suppression of ConA-induced T cell proliferation was compared to unsuppressed PBMC group that was incubated with ConA alone.
We were able to demonstrate T cell suppression by the extracted/purified tacrolimus (Fig. 5) . ConA ability to stimulate the proliferation of CD4 + and CD8 + T cells was remarkably suppressed following tacrolimus pre-incubation as compared to cells treated with ConA alone. Our results are consistent with the previous findings of Takama et al., who reported a significant suppression of T cell proliferation by allogenic mixed lymphocyte reaction in rat splenocytes following tacrolimus treatment (25) (29) . Yet, further studies are needed to explain these observations, which are not in the scope of our current work. Moreover, we proved the activity of our extracted/ purified tacrolimus by its ability to significantly decrease IL-2 protein secretion from isolated PBMCs (Fig. 6 ). IL-2 is a critical cytokine for the maturation, proliferation, and differentiation of T cells (30) . It is produced by stimulated T cells to act in autocrine and paracrine fashions (31, 32) . Our extracted/ purified tacrolimus significantly inhibited ConA-stimulated secretion of IL-2. This is in agreement with the findings of Härtel et al., where IL-2 mRNA and protein levels in whole blood cells stimulated with anti-CD3/anti-CD28 were significantly reduced following tacrolimus pre-incubation (12) . This clearly confirms the immunosuppressive activity of the extracted/purified tacrolimus as it was shown upon binding with FK506 binding protein (FKBP), the complex (FK506-FKBP) has an ability to interact and inhibit calcineurin, resulting in the prevention of IL-2 production and T cell proliferation (20, 33) .
Another direct evidence of the immunosuppressive activity of the extracted/purified tacrolimus is the significant suppression of IFN-γ secretion by isolated PBMCs (Fig. 7) . IFN-γ is produced by multiple subsets of stimulated immune cells including natural killer (NK) cells, NKT cells, Th1 CD4 + cells, and CD8 + T cells (34) . Therefore, the suppressive ability of extracted/purified tacrolimus on ConA-stimulated IFN-γ secretion is evident of retained pharmacological functionality. Supportive evidence has been previously reported proving the inhibitory effect of tacrolimus on IFN-γ production in human PBMC (35) as well as in murine model (36) . This is consistent with our results. It is worth noting that IL-2 inhibition was noticed as early as 24 h in culture as compared to IFN-g, which required 48 h to show significance in inhibition. This is due to the kinetic difference in the production of the two cytokines where IFN-g secretion is slow (37) as compared to that of IL-2 (38). . IL-2 cytokine levels measured in PBMCs supernatants. Filled dots represent IL-2 protein levels secreted in the supernatant of PBMCs stimulated with concanavalin A (ConA), while unfilled dots represent IL-2 protein levels secreted in the supernatant of PBMCs pre-incubated with extracted/purified tacrolimus followed by stimulation with concanavalin A (TAC + ConA). IL-2 secretion was followed for 48-h treatment. Data are presented are mean±SD of at three experiments. Statistical significance was indicated by an asterisk (*). Statistically significant inhibition was noticed after 24 h Fig. 7 . IFN-γ cytokine levels measured in PBMCs supernatants. Filled dots represent IFN-γ protein levels secreted in the supernatant of PBMCs stimulated with concanavalin A (ConA), while unfilled dots represent IFN-γ protein levels secreted in the supernatant of PBMCs pre-incubated with extracted/purified tacrolimus followed by stimulation with concanavalin A (TAC + ConA). IFN-γ secretion was followed for 48-h treatment. Data are presented are mean±SD of at three experiments. Statistical significance was indicated by an asterisk (*). Statistically significant inhibition was noticed only after 48 h CONCLUSIONS To address the question whether there is a quality difference between tacrolimus extracted and purified from expired capsules and reference drug, several analytical methods were employed. These tests assessed the quality and pharmacological activity of tacrolimus extracted/ purified from Prograf® capsules (5 mg) that are beyond their expiration date. The data obtained showed no detectable difference in quality between the reference sample and extracted drug. Moreover, immunosuppressive activity of extracted/purified tacrolimus was evaluated on murine T cells by flow cytometric proliferation analysis and cytokines ELISA. The results showed that the extracted/purified tacrolimus was capable of suppressing the proliferation of stimulated CD4 + and CD8 + T cell subsets and significantly inhibited their secretion of IL-2 and IFN-γ cytokines. Therefore, we concluded that the extracted/purified drug is suitable for reutilization in relevant experimental research. This is a rarely discussed matter although it carries a potential cost savings resulting from reutilization of API's from expired expensive medications especially when industrial reutilization is considered. Our results are concerned with tacrolimus as an individual API. Nonetheless, each API should undergo individual systematic evaluation.
